Rituximab in three children with relapsed/refractory B‐cell acute lymphoblastic leukaemia/Burkitt non‐Hodgkin's lymphoma
Open Access
- 1 April 2004
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 125 (3), 414-415
- https://doi.org/10.1111/j.1365-2141.2004.04925.x
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Induction of Long-Term Remission of a Relapsed Childhood B–Acute Lymphoblastic Leukemia With Rituximab Chimeric Anti-CD20 Monoclonal Antibody and Autologous Stem Cell TransplantationJournal of Pediatric Hematology/Oncology, 2003
- Rituximab for the treatment of refractory autoimmune hemolytic anemia in childrenBlood, 2003
- Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartmentBlood, 2003
- Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in childrenBritish Journal of Haematology, 2001
- The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemiaBlood, 2001
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997